Fig. 4: Development of CXCR4 targeted contrast agent ProCA32.CXCR4 for CXCR4 molecular MR imaging. | Cancer Gene Therapy

Fig. 4: Development of CXCR4 targeted contrast agent ProCA32.CXCR4 for CXCR4 molecular MR imaging.

From: Non-invasive detection and complementary diagnosis of liver metastases via chemokine receptor 4 imaging

Fig. 4

A The working scheme of ProCA32.CXCR4 imaging UM liver metastases in the mouse models. UM cell lines were derived from UM patient tissue. After inoculation of the UM cells in the eye of the mice, metastatic lesions will form in the liver over time. ProCA32.CXCR4 administered through I.V. injection. B Intensity enhancement of UM liver metastatic lesions by MRI molecular imaging. C Relaxivity measurement of ProCA32.CXCR4 and clinical counterparts including Dotarem, Magnevist, Eovist, and ProHance. At 7.0 T magnetic field, ProCA32.CXCR4 exhibited notably higher r1 and r2 values compared to the other gadolinium-based clinical contrast agents. D CXCR4 targeting study of ProCA32.CXCR4 through immunofluorescence staining. Blue fluorescence is the DAPI staining of nucleus. Green fluorescence indicates the fluorescein labeled ProCA32.CXCR4 on Mel290 cells, scale bar, 10 µm. E Quantitative measurement of CXCR4 targeting capability of ProCA32.CXCR4 by ELISA. The Kd value of ProCA32.CXCR4 binding to CXCR4 was 1.19 ± 0.28 µM. F Determination of CXCR4/CXCL12 mediated downstream activity using cAMP assay. Binding of ProCA32.CXCR4 to CXCR4 does not produce any significant cAMP activity, which is very different from antagonist AMD3100.

Back to article page